persovac lyofilizát a rozpouštědlo pro injekční suspenzi
ceva-phylaxia veterinary biologicals co.ltd. - prasat, reprodukční a respirační syndrom (rpo) virus vakcíny - lyofilizát a rozpouštědlo pro injekční suspenzi - Živé virové vakcíny - prasata ve výkrmu
cevac md rispens 800-5000 pfu koncentrát a rozpouštědlo pro injekční suspenzi
ceva-phylaxia veterinary biologicals co.ltd. - influenza virus herpes vakcíny (mareks onemocnění) - koncentrát a rozpouštědlo pro injekční suspenzi - Živé virové vakcíny - kur domácí
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirotika pro systémové použití - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použití této vakcíny musí být v souladu s oficiálními doporučeními.
innovax-nd-ilt
intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - imunologická léčba - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.
ultifend nd ibd
ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - imunologická léčba - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).
meditek ctc 500 mg/g premix pro medikaci krmiva
tekro spol. s r.o. - chlortetracyklin - premix pro medikaci krmiva - tetracykliny - brojleři kura domácího, prasata
locametz
novartis europharm limited - gozetotide - radionuklidové zobrazování - diagnostické radiofarmaka - tento léčivý přípravek je určen pouze pro diagnostické účely. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
aminoplasmal b.braun 10% infuzní roztok
b. braun melsungen ag, melsungen array - 790 isoleucin; 829 leucin; 4566 lysin-acetÁt; 13214 monohydrÁt lysinu; 2445 methionin; 1117 fenylalanin; 1459 threonin; 1503 tryptofan; 1514 valin; 96 arginin; 717 histidin; 27 alanin; 55 glycin; 103 kyselina asparagovÁ; 665 kyselina glutamovÁ; 4147 prolin; 4717 serin; 1507 tyrosin - infuzní roztok - aminokyseliny
aminoplasmal b.braun 5% e infuzní roztok
b. braun melsungen ag, melsungen array - 790 isoleucin; 829 leucin; 851 lysin-hydrochlorid; 2445 methionin; 1117 fenylalanin; 1459 threonin; 1503 tryptofan; 1514 valin; 96 arginin; 717 histidin; 27 alanin; 55 glycin; 103 kyselina asparagovÁ; 665 kyselina glutamovÁ; 4147 prolin; 4717 serin; 1507 tyrosin; 1306 trihydrÁt natrium-acetÁtu; 2458 hydroxid sodnÝ; 1170 kalium-acetÁt; 1322 chlorid sodnÝ; 856 hexahydrÁt chloridu hoŘeČnatÉho; 1341 dodekahydrÁt hydrogenfosforeČnanu sodnÉho - infuzní roztok - roztoky pro parenterÁlnÍ vÝŽivu, kombinace